COMPANY
inSoma Bio, Inc.
Timeline
- Trial start Not phased (device or behavioral study): First-in-Human Safety Study for Fractomer™ Biomatrix source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07151638 | First-in-Human Safety Study for Fractomer™ Biomatrix | Not phased (device or behavioral study) | Suspended | Aug 11, 2025 | Dec 22, 2026 (estimated) |
NIH awards 7
- NIH award 1R43GM153037-01A1 FY2024: $293,983 awarded for that fiscal year; activity R43 (SBIR); PI ROBERTS, STEFAN; recipient as written: INSOMA BIO, INC., DURHAM, NC. An off the shelf alternative to fat transfer for source ↗
- NIH award 1R41NS135845-01A1 FY2024: $296,151 awarded for that fiscal year; activity R41 (STTR); PI ROBERTS, STEFAN; recipient as written: INSOMA BIO, INC., DURHAM, NC. Enhancing Peripheral Nerve Repair with an Inject source ↗
- NIH award 5R44CA244110-03 FY2023: $1,035,879 awarded for that fiscal year; activity R44 (SBIR); PI ROBERTS, STEFAN; recipient as written: INSOMA BIO, INC., DURHAM, NC. A recombinant matrix to improve autologous tissu source ↗
- NIH award 1R43GM149096-01A1 FY2023: $282,373 awarded for that fiscal year; activity R43 (SBIR); PI ROBERTS, STEFAN; recipient as written: INSOMA BIO, INC., DURHAM, NC. A recombinant elastin skin substitute for the t source ↗
- NIH award 2R44CA244110-02A1 FY2022: $936,817 awarded for that fiscal year; activity R44 (SBIR); PI ROBERTS, STEFAN; recipient as written: INSOMA BIO, INC., DURHAM, NC. A recombinant matrix to improve autologous tissu source ↗
- NIH award 1R43DK129121-01 FY2021: $290,768 awarded for that fiscal year; activity R43 (SBIR); PI ROBERTS, STEFAN; recipient as written: INSOMA BIO, INC., DURHAM, NC. Fully defined matrices for organoid culture source ↗
- NIH award 1R41CA244110-01A1 FY2019: $254,627 awarded for that fiscal year; activity R41 (STTR); PI ROBERTS, STEFAN; recipient as written: INSOMA BIO, INC., DURHAM, NC. A recombinant matrix to improve autologous tissu source ↗